Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Congenital hypogonadotropic hypogonadism (CHH) is characterized by lack of normal pubertal development due to deficient gonadotropin-releasing hormone (GnRH) secretion or action, and is caused by genetic defects in several genes. Mutations in the CHD7 gene cause CHARGE syndrome (Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation of growth and development, Genital hypoplasia and Ear abnormalities), but have also been found in patients with isolated CHH. The aim of this study was to identify CHD7 mutations in patients with CHH. Fifty Portuguese patients with CHH were screened for mutations in the CHD7 gene by DNA sequencing. Eight (16%) patients had CHD7 rare sequence variants that consisted of six missense (p.Gly388Glu, p.His903Pro, p.Thr1082Ile, p.Val1452Leu, p.Asp1854Gly, and p.Arg2065His) and two synonymous (p.Ser559Ser, and p.Ala2785Ala) mutations. Five of these mutations have never been reported before. Three CHD7 mutations occurred in patients that had mutations in additional CHH-genes. This study uncovered novel genetic variants that expand the known spectrum of mutations associated with CHH. The frequency of CHD7 mutations in this cohort was higher than that of other major CHH-genes and confirms the importance of including CHD7 in the genetic testing of CHH, even in the absence of additional CHARGE features.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367338 | PMC |
| http://dx.doi.org/10.1038/s41598-018-38178-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Non-Functional Pancreatic Neuroendocrine Tumors Correlate with Poor Patient Prognosis.
Mod Pathol
August 2025
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address:
Pancreatic neuroendocrine tumors (PanNETs) exhibit heterogeneous clinical behavior, and a growing number of NF-PanNETs have been discovered incidentally. While chromatin remodeling and telomere maintenance gene alterations, such as ATRX and DAXX mutations, are well-established in the metastatic progression of PanNETs, many tumors lack known driver mutations. To identify additional prognostic biomarkers and alternative oncogenic mechanisms in primary non-functional pancreatic neuroendocrine tumors (NF-PanNETs), we employed whole transcriptome sequencing (WTS) on 73 non-syndromic NF-PanNETs with extended clinical follow-up (>4 years).
View Article and Find Full Text PDFCHARGE syndrome is a developmental disorder that affects 1 in 10,000 births, and patients exhibit both physical and behavioral characteristics. mutations in cause 67% of CHARGE syndrome cases. CHD7 is a DNA-binding chromatin remodeler with thousands of predicted binding sites in the genome, making it challenging to define molecular pathways linking loss of to CHARGE phenotypes.
View Article and Find Full Text PDFCHD7 regulates definitive endodermal and mesodermal development from human embryonic stem cells.
Stem Cell Res Ther
June 2025
Department of Allied Health Sciences, University of Connecticut, 1390 Storrs Road, Storrs, 06269, CT, USA.
Background: CHD7 encodes an ATP-dependent chromodomain helicase DNA binding protein; mutations in this gene lead to multiple developmental disorders, including CHARGE (Coloboma, Heart defects, Atresia of the choanae, Retardation of growth and development, Genital hypoplasia, and Ear anomalies) syndrome. How the mutations cause multiple defects remains largely unclear. Embryonic definitive endoderm (DE) generates the epithelial compartment of vital organs such as the thymus, liver, pancreas, and intestine.
View Article and Find Full Text PDFA novel cardiomyopathy phenotype linked to a CHD7 missense variant.
Sci Rep
June 2025
Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA.
Loss of function in the chromatin remodeler CHD7 causes CHARGE syndrome, characterized by variable penetrance and diverse abnormalities. However, establishing genotype-phenotype correlations has been challenging, as most CHD7 inactivating mutations are null alleles. Through CHD7 missense variant analysis at potential phosphorylation sites, we identified T730 (T720 in mice) as a critical residue associated with pathogenesis.
View Article and Find Full Text PDFChromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progression.
Cell Rep
May 2025
Department of Biochemistry and Cellular Biology, National Center of Neurology and Psychiatry (NCNP), Tokyo 187-8052, Japan; Department of Neuro-oncology, Institute of Brain Science, Graduate School of Medical Sciences, Nagoya City University, Aichi 467-8601, Japan. Electronic address:
Medulloblastoma (MB), a common malignant pediatric brain tumor arising in the cerebellum, is characterized by mutations in chromatin modifiers, highlighting the significance of chromatin modification abnormalities in its progression. While animal models have effectively demonstrated this, a comprehensive evaluation of the oncogenic potential of these mutations remains incomplete. In this study, we use CRISPR-mediated gene editing to knock out chromatin modifier genes mutated in human SHH MB, along with the Ptch1 gene, in cerebellar granule neuron progenitors of neonatal mice.
View Article and Find Full Text PDF